» Articles » PMID: 32092393

MiRNA Polymorphisms and Risk of Premature Coronary Artery Disease

Overview
Date 2020 Feb 25
PMID 32092393
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: Several microRNA (miRNA) polymorphisms have been associated with susceptibility to specific health disorders, including cardiovascular diseases. The aim of the present study was to investigate whether four well-studied miRNA polymorphisms in non-Caucasian populations, namely miR146a G>C (rs2910164), miR149 C>T (rs2292832), miR196a2 C>T (rs11614913) and miR499 A>G (rs3746444), contribute to the risk for the development of premature Coronary Artery Disease (CAD) in the Greek population.

Methods: We used a case-control study to examine these associations in 400 individuals: 200 CAD patients [including a subgroup of myocardial infraction (MI) patients] and 200 healthy controls, all of Greek origin. MiRNA polymorphisms were genotyped using three different assays: Polymerase chain reaction - restriction fragment length polymorphism (PCR-RFLP), High resolution Melting (HRM) and Sanger sequencing.

Results: Two of these polymorphisms, miR196a2 C>T (rs11614913) and miR499 A>G (rs3746444) were found to be strongly associated with increased risk for CAD (p=0.0388 and p=0.0013, respectively) and for MI (p=0.0281 and p=0.0273, respectively). Furthermore, miR146C-miR149C-miR196T-miR499G allele combination appeared to be significantly related to CAD (p=0.0185) and MI (p=0.0337) prevalence.

Conclusions: Our results suggest that at least two of the studied polymorphisms, miR196a2 C>T (rs11614913) and miR499 A>G (rs3746444), as well as the miR146C-miR149C-miR196T-miR499G allele combination could represent useful biomarkers of CAD and/or MI susceptibility in the Greek population. These special genetic characteristics, in combination with environmental factors and personal habits, might contribute to CAD and/or MI prevalence.

Citing Articles

Expression level of miR-146a is associated with the coronary lesion severity and clinical prognosis in patients with unstable angina pectoris.

Shi B, Wang X, Xue T, Liu J, Wu W, Luo Y Int J Cardiol Cardiovasc Risk Prev. 2025; 24:200367.

PMID: 39872631 PMC: 11770491. DOI: 10.1016/j.ijcrp.2025.200367.


Genetic Associations of Plasminogen Activator Inhibitor-1-Related miRNA Variants with Coronary Artery Disease.

Ha Y, Sung J, Ryu C, Ko E, Park H, Park H Int J Mol Sci. 2024; 25(21).

PMID: 39519081 PMC: 11546797. DOI: 10.3390/ijms252111528.


Non-Coding RNA Involved in the Pathogenesis of Atherosclerosis-A Narrative Review.

Kielbowski K, Zychowska J, Bakinowska E, Pawlik A Diagnostics (Basel). 2024; 14(17).

PMID: 39272765 PMC: 11394555. DOI: 10.3390/diagnostics14171981.


MicroRNA Expression in Patients with Coronary Artery Disease and Hypertension-A Systematic Review.

Kondracki B, Kloda M, Jusiak-Kloda A, Kondracka A, Wacinski J, Wacinski P Int J Mol Sci. 2024; 25(12).

PMID: 38928136 PMC: 11204345. DOI: 10.3390/ijms25126430.


m6A regulator-mediated RNA methylation modification patterns are involved in immune microenvironment regulation of coronary heart disease.

Li Z, Song Y, Wang M, Shen R, Qin K, Zhang Y Front Cardiovasc Med. 2022; 9:905737.

PMID: 36093132 PMC: 9453453. DOI: 10.3389/fcvm.2022.905737.